INDICATIONS AND USAGE（适应症）

Invasive Aspergillosis

CRESEMBA® is an azole antifungal indicated for patients 18 years of age and older for the treatment of invasive aspergillosis.

Invasive Mucormycosis

CRESEMBA is an azole antifungal indicated for patients 18 years of age and older for the treatment of invasive mucormycosis.

DOSAGE（服用剂量）

Intravenous formulation must be administered via an infusion set with an in-line filter (pore size 0.2 to 1.2 micron).

Infuse the intravenous formulation over a minimum of 1 hour in 250 mL of a compatible diluent, to reduce the risk for infusion-related reactions. Do not administer as an intravenous bolus injection.

Do not infuse CRESEMBA with other intravenous medications.

Flush intravenous lines with 0.9% sodium chloride injection, USP or 5% dextrose injection, USP prior to and after infusion of CRESEMBA.

After dilution of the intravenous formulation, avoid unnecessary vibration or vigorous shaking of the solution. Do not use a pneumatic transport system.

CRESEMBA for Injection 372 mg of isavuconazonium sulfate per vial

Loading Dose: 1 reconstituted vial (372 mg) intravenously every 8 hours for 6 doses (48 hours)

Maintenance Dose: 1 reconstituted vial (372 mg) intravenously once daily

ADVERSE REACTIONS（不良反应）

Hepatic Adverse Drug Reactions

Infusion-Related Reactions

Hypersensitivity Reactions

Embryo-Fetal Toxicity

For full information, please refer to:

https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/8f7f73b8-586a-4df0-935f-fecd4696c16c/spl-doc?hl=Cresemba

Isavuconazoleinformation